Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
IRD
IRD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IRD News
Opus Genetics Plans to Raise $25M in Private Placement
2d ago
seekingalpha
Opus Genetics Secures $25 Million in Private Placement Financing
2d ago
Newsfilter
Opus Genetics Insider Cam Gallagher Acquires 164,000 Shares of IRD for $323,693
Jan 02 2026
NASDAQ.COM
Opus Genetics Grants 50,000 Stock Options to Attract New Employee
Dec 16 2025
Globenewswire
Opus Genetics CEO to Present at J.P. Morgan 2026 Healthcare Conference on January 15, 2026
Dec 11 2025
Globenewswire
Opus Genetics CEO to Present at J.P. Morgan 2026 Healthcare Conference on January 15, 2026
Dec 11 2025
Newsfilter
Opus Genetics Advances as Eye Disease Research Continues Unchanged
Dec 09 2025
SeekingAlpha
Opus Genetics Advances BEST1 Clinical Trial as First Participant Shows Positive Safety Results
Dec 09 2025
Newsfilter
Opus Genetics Grants 124,000 Stock Options to Attract New Employees
Dec 02 2025
Globenewswire
Opus Genetics Approves 124,000 Stock Options as Employee Incentives
Dec 02 2025
Newsfilter
Top Analysts Recommend Purchasing These 3 Penny Stocks Immediately
Nov 21 2025
TipRanks
Opus Genetics Begins Dosing First Participant in Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Best Disease
Nov 13 2025
Newsfilter
Opus Genetics, Inc. Reports Q3 Loss That Falls Short of Expectations
Nov 12 2025
NASDAQ.COM
Celestica Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations
Oct 16 2025
Benzinga
Chardan Capital Begins Coverage of Opus Genetics with a Buy Rating and Sets Price Target at $9
Oct 16 2025
Benzinga
Searching for a Leading Momentum Stock? Here's Why Opus Genetics, Inc. (IRD) is an Excellent Option
Oct 01 2025
NASDAQ.COM
Show More News
